Clinical-grade neuromodulation platform scaling to providers
Ampa operates a neuromodulation platform targeting clinician adoption, running a Python + Node.js + TypeScript stack on AWS with React Native mobile and web interfaces. The company is wrestling with provider onboarding friction (closing accounts, clinician readiness) while simultaneously building operational dashboards and patient data pipelines — a sign of moving from early proof-of-concept toward production-grade clinical deployment. Senior-heavy hiring (9 of 13 active roles) paired with lean support and sales teams suggests they're prioritizing engineering stability and clinical validation over volume sales.
Ampa develops a neuromodulation platform designed to broaden access to neurological and mental health treatments. Founded in 2022 and based in Palo Alto, the company is currently a 11–50 person operation. The product surfaces through web and tablet interfaces targeting healthcare providers, with backend infrastructure for patient session data, telemetry management, and operational reporting. Core challenges center on provider adoption (account closing, clinician onboarding) and post-market quality — typical friction points for hardware-software hybrid medical devices scaling clinical workflows.
Python, Node.js, TypeScript, React Native, and React on the application layer; PostgreSQL for data; AWS (RDS, ECS, Lambda, EventBridge, QuickSight) for infrastructure; Jira, GitHub Actions, and TestRail for development operations.
Scaling provider access to their neuromodulation platform; building web and tablet interfaces; implementing software verification and validation protocols; developing secure APIs; deploying operational dashboards; and managing patient session data pipelines and device telemetry.
Other companies in the same industry, closest in size